Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System

About this update from Microbot Medical Inc.

Leading academic center with multi-hospital and multi-state health system deepens Company’s footprint in the Northeast U.S.The Company now has multiple accounts and hospitals that have adopted the LIBERTY System across seven states in the U.S. HINGHAM, Mass., June 23, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that a globally recognized academic center headquartered in Pennsylvania is the first in the state to adopt the LIBERTY System, allowing the Company to further expand its presence in the Northeast U.S., joining other health systems in New York City and Boston that have also adopted the LIBERTY System. This latest customer operates multiple hospitals and multispecialty centers serving patients in the highly concentrated Pennsylvania and New Jersey regions and is the second customer with hospitals and medical facilities spanning two states, with the NYC-based customer also having medical facilities in New Jersey. The Company now has accounts in seven states across the Eastern U.S., with multiple hospitals across their health systems, having already adopted the LIBERTY System. This level of progress reflects the Company’s focused commercial efforts, and with the recent transition into the full market release in the second quarter, the Company is planning to expand its sales territory to the West Coast. Furthermore, the recent agreement to expand access to the LIBERTY System across certain U.S. federal healthcare systems, including those serving veterans and military patient populations, is further strengthening the Company’s confidence in accelerating adoption of the LIBERTY System within existing and new accounts. “This is a very encouraging development and demonstrates continued customer adoption across our sales territories, including some of the most prestigious health systems in the U.S., which we believe further reinforces our commercialization strategy,” commented Harel Gadot, CEO, President and Chairman. “Additionally, the interest we are experiencing across our other sales territories that started with the recent full market release helps support our plan to expand our sales footprint into the Western U.S., while continuing to establish our infrastructure in the international markets.”About Microbot Medical Microbot Medical Inc.&nbsp...

View stock analysis, news, and events for Microbot Medical Inc.